Summary: In adults starting or intensifying insulin within a 24-week telehealth programme, Bluetooth-enabled glucometers achieved similar HbA1c reductions to traditional meters but were associated with fewer emergency department visits (4.1% vs 16.7%).
PICO Summary
| Element | Detail |
|---|---|
| Population | 120 adults aged 21–70 with type 2 diabetes requiring insulin initiation or intensification, in a 24-week telehealth titration programme. |
| Intervention | Bluetooth-enabled glucometer (BTG) with automatic data transmission during biweekly nurse-educator teleconsultations. |
| Comparison | Traditional glucometer (TG) with manual reporting under the same telehealth protocol. |
| Outcome | Both arms achieved significant HbA1c falls (TG -2.8% then -3.1%; BTG -2.23% then -2.18%) with no between-group difference. BTG had fewer ED visits (4.1% vs 16.7%; p=0.039). Diabetes-related distress improved similarly in both. |
Bluetooth vs traditional glucometers in telehealth insulin titration
RCT · type 2 diabetes · 24 weeks
Bluetooth connectivity gave no HbA1c advantage over traditional meters, but was linked to fewer emergency department visits. The structured nurse-educator telehealth protocol, not the device, appears to drive glycaemic gains.
Expert Commentary
It is tempting to assume that a connected device must beat a manual one, so I value a trial willing to test that assumption rather than sell it. The verdict on the headline question is clear and slightly deflating for the technology: Bluetooth connectivity did nothing extra for HbA1c, and both arms achieved the kind of two to three point reductions that tell me the real engine here is the structured biweekly nurse-educator contact, not the meter. That is the lesson I take to my own service planning. The ED-visit difference is genuinely interesting and, if real, clinically meaningful, but I am cautious because it was a secondary endpoint in a modest single-centre study, exactly the setting where a striking secondary result can be a chance finding or driven by unmeasured confounders. Can I use this with my patients? Yes, in a reassuring way: when budgets are tight I can lean on a good protocol and an ordinary glucometer without feeling I am shortchanging anyone’s glycaemic outcome, while reserving connected devices for higher-risk or complex patients where earlier intervention might matter. I would want the ED signal confirmed in a larger trial before I justify the devices on that basis alone.
References
Lian X, Liew HL, Lee YS, et al. Telehealth insulin titration in adults with diabetes: a randomized controlled trial comparing bluetooth-enabled versus traditional glucometers. Front Endocrinol (Lausanne). 2025;16:1724811. doi:10.3389/fendo.2025.1724811